查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750708

遺傳性癌症檢測市場規模、佔有率、趨勢分析報告：按癌症、技術、檢測類型、最終用途、地區、細分市場預測，2025-2030 年

Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology, By Test Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

遺傳性癌症檢測市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球遺傳性癌症檢測市場規模預計到2030年將達到94.529億美元，2025年至2030年期間的複合年成長率為12.9%。

政府支持、醫療資金以及直接面對消費者 (DTC) 的基因檢測平台的成長推動了該市場的發展。遺傳性癌症佔所有癌症的 10%，其餘 90% 為散發性癌症。我們需要滿足日益成長的遺傳性癌症檢測需求，這可以透過政府措施和資金投入來實現，以滿足醫療保健需求。政府旨在預防癌症和基因研究的舉措和資金正在顯著推動遺傳性癌症檢測市場的發展。

許多國家已訂定政策，將基因檢測作為其癌症風險評估計劃的一部分，並通常提供檢測費用的財務支持。例如，美國國家綜合癌症網路 (NCCN) 於 2025 年 1 月推出了一項新資源，旨在為個人提供有關遺傳性和遺傳性癌症風險的最新建議。該指南重點關注遺傳性乳癌、卵巢癌、胰腺癌和前列腺癌，也可透過應用程式取得。該指南提供了清晰易懂的指導，指導人們如何評估和檢測可能增加癌症風險的遺傳基因突變。訊息以清晰易懂的方式呈現。

遺傳性癌症檢測的監管核準確保了用於評估癌症風險的基因檢測符合準確性、安全性和可靠性的嚴格標準。 FDA 將這些檢測歸類為醫療設備，必須經過全面評估才能核准上市。 2023 年 9 月，美國食品藥物管理局(FDA) 首次核准了一種用於評估多種癌症遺傳易感性的 DNA 檢測。這項里程碑式的核准允許透過次世代定序 (NGS) 存取與多種癌症（包括乳癌、卵巢和結直腸癌）風險升高相關的多個突變基因，以提供高靈敏度、快速和準確的見解。透過識別這些遺傳突變，該檢測為個人提供了有價值的資訊，以指南早期發現、預防措施和個性化治療計劃。這項核准標誌著基因檢測和癌症預防領域的一個重要里程碑，使個人能夠採取積極主動的措施來管理自己的健康。

各國政府意識到基因檢測可能帶來醫療保健領域的革命，已啟動多項舉措，旨在將基因檢測服務整合到公共衛生基礎設施中。美國國家癌症實驗室邁出了重要一步，向喬治城大學倫巴第綜合癌症中心和新澤西州羅格斯大學癌症實驗室的研究人員提供了320萬美元的津貼。這項津貼將支持一項為期五年的研究，該研究將招募428名符合國家遺傳性癌症檢測指南的黑人癌症患者參加隨機對照試驗，並評估這些干預措施對基因教育參與度、檢測接受度、知情決策和社會心理結果的影響。透過消除基因檢測的障礙並吸收社區意見，該研究旨在提高篩檢的可近性，改善癌症的醫療管理，並最終促進癌症治療中的健康公平。

市場上出現了 Myriad Genetics, Inc.、Bio-Rad Laboratories、F. HOFFMANN-LA ROCHE LTD 和 Illumina, Inc. 等主要參與企業的活動。這些參與企業正在積極尋求美國FDA的產品核可，以滿足全球客戶的需求。例如，2024 年 6 月，Myriad Genetics, Inc. 宣布正在進行的創新：MyChoice CDx HRD 和 BRACAnalysis CDx 種系伴隨診斷測試，以透過研究合作加強產品系列。此外，Myriad 已啟動多項合作，探索 MRD 在各種癌症中的潛力。此外，精準醫療癌症線上篩檢工具的開發將使病患教育能夠改善結果。例如，2025 年 1 月，Myriad Genetics, Inc. 發表了一項研究表明，結合線上篩檢工具和基因教育，患者更有可能完成遺傳性癌症檢測。這種方法強調了數位工具和教育在提高參與度和對癌症風險評估基因檢測的興趣方面的重要性。

因此，基因檢測技術的進步、政府舉措和資金的增加以及監管核准的加速正在推動早期檢測和疾病預防市場的成長。

遺傳性癌症檢測市場報告重點

  • 按癌症類別分類，乳癌將在2024年佔據最大的收益佔有率，達到12.45%。由於次世代定序儀(NGS) 和人工智慧 (AI) 的進步，遺傳性乳癌檢測市場正在不斷擴大，這些技術能夠實現全面的風險評估。認知度的提高、政府的措施以及保險覆蓋範圍的擴大，進一步推動了該檢測的普及。這些技術創新正在促進早期發現和個人化預防策略，從而改善患者的預後。
  • 從技術角度來看，分子檢測將佔據市場主導地位，到2024年將佔據56.36%的最大佔有率。由於癌症盛行率的上升以及新一代快速基因分析技術的進步，遺傳性癌症檢測市場中的分子檢測細分市場正在不斷擴大。這些技術提高了診斷的準確性，並促進了個人化治療策略的實施。此外，人們意識的增強和保險覆蓋率的提高也推動了分子檢測的普及。
  • 根據測試類型，預測性基因檢測預計將成為遺傳性癌症檢測市場的主導部分，到 2024 年將佔據 66.49% 的佔有率。遺傳疾病盛行率的上升和對預防性醫療保健的日益重視進一步推動了預測性基因檢測的採用。
  • 從最終用途來看，到2024年，醫院將佔據最大的市場佔有率，達到55.11%，並在其他細分市場中保持成長。醫院正在與研究型大學合作，以推動該市場的成長。
  • 由於許多主要市場參與企業的存在、次世代定序(NGS) 的進步、對遺傳風險的認知不斷提高以及保險覆蓋範圍的擴大，北美在全球市場佔據主導地位。
  • 由於主要企業利用創新技術進行擴張以及診斷研究能力的加速，亞太地區預計將以最快的速度成長，2025 年至 2030 年期間的複合年成長率達到 14.3%。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 遺傳性癌症檢測市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 遺傳性癌症檢測市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析

第4章遺傳性癌症檢測市場：按癌症類型進行的估計和趨勢分析

  • 細分儀表板
  • 遺傳性癌症檢測市場：癌症變異分析
  • 遺傳性癌症檢測市場規模及趨勢分析（依癌症類型，2018-2030）
  • 2018-2030年市場規模、預測及趨勢分析
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 子宮頸癌
  • 卵巢癌
  • 攝護腺癌
  • 胃癌
  • 黑色素瘤
  • 肉瘤
  • 子宮癌
  • 胰臟癌
  • 其他

第5章遺傳性癌症檢測市場：依技術、估計和趨勢分析

  • 2024 年及 2030 年技術市場佔有率
  • 細分儀表板
  • 全球遺傳性癌症檢測市場（依技術格局）
  • 2018-2030年市場規模、預測及趨勢分析
  • 細胞遺傳學
  • 生化
  • 分子檢測

第6章 測試類型市場：按測試類型進行的估計和趨勢分析

  • 2024 年和 2030 年測試類型市場佔有率
  • 細分儀表板
  • 全球遺傳性癌症檢測市場按檢測類型展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 預測測試
  • 診斷測試

第7章 最終用途市場：依最終用途的估算與趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 全球遺傳性癌症檢測市場（依最終用途）展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 診斷中心
  • 醫院
  • 診所

第 8 章：遺傳性癌症檢測市場：區域、估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 2024年主要企業市場佔有率分析
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Bio-Rad Laboratories
    • CSL Ltd
    • Qiagen NV
    • Danaher Corporation
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • EUROFINS SCIENTIFIC
    • F. HOFFMANN-LA ROCHE LTD
    • Illumina, Inc.
Product Code: GVR-4-68040-588-5

Hereditary Cancer Testing Market Growth & Trends:

The global hereditary cancer testing market size is expected to reach of USD 9,452.9 million by 2030, and is projected to grow at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is accelerating, due to government support and healthcare funding and growth of direct-to-consumer (DTC) genetic testing platforms. Hereditary cancer accounts overall to 10% and remaining 90% is sporadic cancer. There arises a need to address this growing demand of hereditary cancer which may be possible by government initiatives and funding to meet the healthcare demand. Government initiatives and funding aim at cancer prevention and genetic research significantly drive the hereditary cancer testing market.

Many countries have introduced policies that promote genetic testing as part of cancer risk assessment programs, often providing financial support for testing costs. For example, the National Comprehensive Cancer Network (NCCN), in January 2025, released a new resource designed to provide individuals with the most up-to-date recommendations on hereditary and familial cancer risks. These guidelines focus on hereditary breast, ovarian, pancreatic and prostate cancer which is available also through and app. It offers clear, easy-to-understand guidance on how to assess and test for inherited genetic mutations that may increase the risk of cancer. The information is available in a straightforward and accessible way for better comprehension.

Regulatory approvals for hereditary cancer testing ensures that genetic tests used to assess cancer risk meet rigorous standards for accuracy, safety, and reliability. The FDA classifies these tests as medical devices, and they must undergo thorough evaluation before receiving approval for market use. U.S. Food and Drug Administration (FDA) in September 2023, granted its first-ever marketing authorization for a DNA test designed to assess the genetic predisposition to multiple types of cancer. This groundbreaking approval can access multiple variant genes through next generation sequencing (NGS) which are linked to an increased risk of several cancers, including breast, ovarian, and colorectal cancers to provide insights with sensitivity, speed and accuracy. By identifying these inherited genetic mutations, the test provides individuals with valuable information to guide early detection, preventive measures, and personalized treatment plans. This approval marks a significant milestone in the field of genetic testing and cancer prevention, empowering individuals to take proactive steps toward managing their health.

Recognizing the potential of genetic testing in revolutionizing healthcare, government launches several initiatives aimed at integrating genetic services into the public health infrastructure. One significant stride taken by National Cancer Institute that awarded USD 3.2 million grant to researchers at Georgetown University's Lombardi Comprehensive Cancer Center and the Rutgers Cancer Institute of New Jersey. This funding supports a five-year study enrolling 428 Black cancer patients who meet national guidelines for hereditary cancer testing into a randomized controlled trial and will evaluate the impact of these interventions on genetic education engagement, testing uptake, informed decision-making, and psychosocial outcomes. By addressing barriers to genetic testing and incorporating community input, the research aimed at improving access to screening, and medical management of cancers, ultimately advancing health equity in oncology care.

The market has been witnessing activity of the key players such as Myriad Genetics, Inc., Bio-Rad Laboratories, F. HOFFMANN-LA ROCHE LTD and Illumina, Inc. these players are actively engaged in seeking product approvals from USFDA to meet the need of global customers. For instance, in June 2024, Myriad Genetics, Inc, announced its ongoing innovations: MyChoice CDx HRD and BRACAnalysis CDx Germline Companion Diagnostic Tests for enhancing its product portfolio through research collaborations. Additionally, Myriad has initiated multiple research collaborations to investigate the potential of MRD in various cancers. Furthermore, developments in precision medicine online screening tools for cancer enable patient education for improved outcomes. For instance, in January 2025, Myriad Genetics, Inc, announced a study showing that patients were more likely to complete hereditary cancer testing when using an online screening tool combined with genetic education. This approach highlights the importance of digital tools and education in increasing engagement and participation in genetic testing for cancer risk assessment.

Thus, technological advancements in genetic testing, growing government initiatives and funding support and accelerated regulatory approvals are boosting the market growth for early detection and disease prevention.

Hereditary Cancer Testing Market Report Highlights:

  • Based on cancer, breast cancer accounted for largest revenue share of 12.45% in 2024. The hereditary breast cancer testing market is expanding due to advancements in next-generation sequencing (NGS) and artificial intelligence (AI), enabling comprehensive risk assessments. Increased awareness, government initiatives, and expanded insurance coverage further drive adoption. These innovations facilitate early detection and personalized prevention strategies, enhancing patient outcomes.
  • Based on technology, molecular testing dominated the market and accounted for the largest share of 56.36% in 2024.The molecular testing segment in the hereditary cancer testing market is expanding due to rising prevalence of cancer, advancements in next-generation and quick genetic analysis. These technologies enhance diagnostic accuracy and facilitate personalized treatment strategies. Additionally, increased awareness and insurance coverage are driving adoption.
  • Based on test type, in 2024, predictive genetic testing emerged as the dominant segment in the hereditary cancer testing market, capturing 66.49% of the share. The increasing prevalence of genetic disorders and a growing emphasis on preventive healthcare further drive the adoption of predictive genetic tests.
  • Based on end use, hospitals dominated the end-use segments with the largest market share of 55.11% in 2024 and were the fastest growing among the other segments over the period. Hospitals in collaboration with research universities are boosting the growth for this market.
  • North America dominated the global market due to the presence of a large number of major market players, advancements in next-generation sequencing (NGS), increasing awareness of genetic risks, and expanded insurance coverage.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 14.3% from 2025 to 2030, due to expansion by key players with innovative technologies coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Cancer
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Cancer outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Test Type outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Cancer Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements of genetic testing in cancer detection
      • 3.2.1.2. Integration with precision medicine
      • 3.2.1.3. Growing awareness through public and government initiatives
      • 3.2.1.4. Rising prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs and limited insurance coverage
  • 3.3. Hereditary Cancer Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Hereditary Cancer Testing Market: Cancer Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hereditary Cancer Testing Market: Cancer Movement Analysis
  • 4.3. Hereditary Cancer Testing Market Size & Trend Analysis, by cancer, 2018 to 2030 (USD Million)
  • 4.4. Hereditary Cancer Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Lung Cancer
    • 4.5.1. Lung Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Colorectal Cancer
    • 4.7.1. Colorectal Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Cervical Cancer
    • 4.8.1. Cervical Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Ovarian Cancer
    • 4.9.1. Ovarian Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Prostate Cancer
    • 4.10.1. Prostate Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Stomach/Gastric Cancer
    • 4.11.1. Stomach/Gastric Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Melanoma
    • 4.12.1. Melanoma Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Sarcoma
    • 4.13.1. Sarcoma Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. Uterine Cancer
    • 4.14.1. Uterine Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.15. Pancreatic Cancer
    • 4.15.1. Pancreatic Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.16. Others
    • 4.16.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hereditary Cancer Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Hereditary Cancer Testing Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Cytogenetic
    • 5.5.1. Cytogenetic Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Biochemical
    • 5.6.1. Biochemical Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Molecular Testing
    • 5.7.1. Molecular Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Test type Market: Test Type Estimates & Trend Analysis

  • 6.1. Test type Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Test type Market by Capacity Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Predictive Testing
    • 6.5.1. Predictive Testing Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Diagnostic Testing
    • 6.6.1. Diagnostic Testing Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. End Use Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global End Use Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Diagnostic Centers
    • 7.5.1. Diagnostic Centers Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Hospitals
    • 7.6.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Clinics
    • 7.7.1. Clinics Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Hereditary Cancer Testing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/Reimbursement
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/Reimbursement
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/Reimbursement
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/Reimbursement
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/Reimbursement
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/Reimbursement
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Myriad Genetics, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Services benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Invitae Corporation
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Services benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Services benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. CSL Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Services benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Qiagen NV
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Services benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Danaher Corporation
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Services benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Thermo Fisher Scientific
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Services benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Abbott Laboratories
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Services benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. EUROFINS SCIENTIFIC
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Services benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. F. HOFFMANN-LA ROCHE LTD
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Services benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Illumina, Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Services benchmarking
      • 9.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Hereditary cancer testing market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 4 North America Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 6 North America Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 7 U.S Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 8 U.S Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 10 U.S Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 11 Canada Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 12 Canada Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Canada Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 14 Canada Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 15 Mexico Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 16 Mexico Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Mexico Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 19 Europe Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 20 Europe Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Europe Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 22 Europe Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 23 UK Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 24 UK Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 25 UK Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 26 UK Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 27 Germany Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 28 Germany Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Germany Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Germany Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 31 France Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 32 France Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 33 France Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 34 France Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 35 Italy Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 36 Italy Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Italy Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Italy Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 39 Spain Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 40 Spain Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 41 Spain Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Spain Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 43 Denmark Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 44 Denmark Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Denmark Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 46 Denmark Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 47 Sweden Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 48 Sweden Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Sweden Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 51 Norway Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 52 Norway Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Norway Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Norway Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 59 Japan Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 60 Japan Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 61 Japan Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Japan Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 63 China Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 64 China Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 65 China Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 66 China Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 67 India Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 68 India Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 69 India Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 70 India Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 71 Australia Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 72 Australia Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 73 Australia Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 74 Australia Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 75 South Korea Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 76 South Korea Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 77 South Korea Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 78 South Korea Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 79 Thailand Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 80 Thailand Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 81 Thailand Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 82 Thailand Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 83 Latin America Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 84 Latin America Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 85 Latin America Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 86 Latin America Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 87 Brazil Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 88 Brazil Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 89 Brazil Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 90 Brazil Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 91 Argentina Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 92 Argentina Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 93 Argentina Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 94 Argentina Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 95 MEA Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 96 MEA Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 97 MEA Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 98 MEA Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 99 South Africa Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 100 South Africa Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 101 South Africa Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 102 South Africa Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 103 Saudi Arabia Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 104 Saudi Arabia Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 105 Saudi Arabia Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 107 UAE Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 108 UAE Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 109 UAE Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 110 UAE Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)
  • Table 111 Kuwait Hereditary cancer testing market, by cancer, 2018 - 2030 (USD Million)
  • Table 112 Kuwait Hereditary cancer testing market, by technology, 2018 - 2030 (USD Million)
  • Table 113 Kuwait Hereditary cancer testing market, by test type, 2018 - 2030 (USD Million)
  • Table 114 Kuwait Hereditary cancer testing market, by end user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Hereditary cancer testing market: market outlook
  • Fig. 14 Hereditary cancer testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Hereditary cancer testing market driver impact
  • Fig. 20 Hereditary cancer testing market restraint impact
  • Fig. 21 Hereditary cancer testing market strategic initiatives analysis
  • Fig. 22 Hereditary cancer testing market: Cancer movement analysis
  • Fig. 23 Hereditary cancer testing market: Cancer outlook and key takeaways
  • Fig. 24 Hereditary cancer Testing market estimates and forecast, 2018 - 2030
  • Fig. 25 Hereditary cancer testing Market: Technology movement analysis
  • Fig. 26 Hereditary cancer testing market: Technology outlook and key takeaways
  • Fig. 27 Cytogenetic market estimates and forecasts, 2018 - 2030
  • Fig. 28 Biochemical market estimates and forecasts,2018 - 2030
  • Fig. 29 Molecular Testing market estimates and forecasts,2018 - 2030
  • Fig. 30 Hereditary cancer testing Market: Test Type movement analysis
  • Fig. 31 Hereditary cancer testing Market: Test Type outlook and key takeaways
  • Fig. 32 Predictive Testing market estimates and forecasts, 2018 - 2030
  • Fig. 33 Diagnostic Testing market estimates and forecasts, 2018 - 2030
  • Fig. 34 Hereditary cancer testing Market: End Use movement analysis
  • Fig. 35 Hereditary cancer testing market: End Use outlook and key takeaways
  • Fig. 36 Diagnostic Centers market estimates and forecasts, 2018 - 2030
  • Fig. 37 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 38 Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global Hereditary cancer testing market: Regional movement analysis
  • Fig. 40 Global Hereditary cancer testing market: Regional outlook and key takeaways
  • Fig. 41 Global Hereditary cancer testing market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America
  • Fig. 49 North America market estimates and forecasts, 2018 - 2030
  • Fig. 50 U.S.
  • Fig. 51 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 52 Canada
  • Fig. 53 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 54 Mexico
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 56 Europe
  • Fig. 57 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 58 UK
  • Fig. 59 UK market estimates and forecasts, 2018 - 2030
  • Fig. 60 Germany
  • Fig. 61 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 62 France
  • Fig. 63 France market estimates and forecasts, 2018 - 2030
  • Fig. 64 Italy
  • Fig. 65 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 66 Spain
  • Fig. 67 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 68 Denmark
  • Fig. 69 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 70 Sweden
  • Fig. 71 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 72 Norway
  • Fig. 73 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 74 Asia Pacific
  • Fig. 75 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 76 China
  • Fig. 77 China market estimates and forecasts, 2018 - 2030
  • Fig. 78 Japan
  • Fig. 79 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 80 India
  • Fig. 81 India market estimates and forecasts, 2018 - 2030
  • Fig. 82 Thailand
  • Fig. 83 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 84 South Korea
  • Fig. 85 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 86 Australia
  • Fig. 87 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 88 Latin America
  • Fig. 89 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 90 Brazil
  • Fig. 91 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 92 Argentina
  • Fig. 93 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 94 Middle East and Africa
  • Fig. 95 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 South Africa
  • Fig. 97 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 98 Saudi Arabia
  • Fig. 99 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 100 UAE
  • Fig. 101 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 102 Kuwait
  • Fig. 103 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 104 Market share of key market players - Hereditary cancer testing market